Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 years.

Date publication

septembre 2025

Journal

Journal of the American Academy of Dermatology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr NARDIN Charlée

Tous les auteurs :
Ruiz ES, Muñoz-Couselo E, Montaudié H, Berciano-Guerrero MA, de la Gala MDCÁ, Charles J, Quéreux G, Nardin C, Tur RY, Dalle S, Beylot-Barry M, Ladwa R, McGrath M, Brungs D, Harris D, Shue H, Tazbirkova A, Fourie S, Malan DR, Oliviero J, Wilcoxen LN, Gray WG, Clingan P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41055628

Résumé

Cosibelimab-ipdl, a high-affinity, programmed death-ligand 1-blocking antibody, is approved by the US Food and Drug Administration for treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation.

Mots clés

advanced cutaneous squamous cell carcinoma, cosibelimab, immune checkpoint inhibitors, immunotherapy, programmed death-ligand 1, skin cancer, skin neoplasms

Référence

J Am Acad Dermatol. 2025 09 29;: